https://www.selleckchem.com/products/arv-771.html
Treatment with immune-checkpoint inhibitors in melanoma patients can cause immune-related adverse effects, such as vitiligo. In vitiligo, specific autoimmunity against melanocytes results in depigmentations of the skin. Melanoma-associated vitiligo occurring in melanoma patients treated with immune-checkpoint inhibitors can be seen as a good prognostic sign as higher survival rates in melanoma-associated vitiligo cases have been reported.Areas covered This review gives an insight in the pathophysiology, clinical presentation and managem
Like
Comment
Share
